NewAmsterdam Pharma Company N.V. (NAMS) Ownership
NAMS ownership summary
as of October 17, 2026- Institutions
- 106.5% of shares outstanding
- Insiders
- 0.90% of shares outstanding
- Shares outstanding
- 119.5M
- Float
- 81.5M shares available to trade
- Short interest
- 18.64% 19.0M shares short
- Days to cover
- 10.36 short interest up 21.6% vs prior month
- Institutions 106.54%
- Insiders 0.90%
NAMS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 15.13% | 18.1M | $358.7M | +1.1M (+6.8%) | June 30, 2026 |
| 2 | Capital World Investors | 10.23% | 12.2M | $242.5M | +1.1M (+10.1%) | June 30, 2026 |
| 3 | FMR Inc | 8.65% | 10.3M | $205.0M | +1.6M (+18.0%) | June 30, 2026 |
| 4 | RA Capital Management, LLC | 7.99% | 9.6M | $189.4M | — | June 30, 2026 |
| 5 | FCPM III SERVICES BV | 7.10% | 8.5M | $168.4M | −708,547 (−7.7%) | June 30, 2026 |
| 6 | Deerfield Management Co | 3.57% | 4.3M | $84.6M | — | June 30, 2026 |
| 7 | Viking Global Investors LP | 3.52% | 4.2M | $83.4M | — | June 30, 2026 |
| 8 | Bain Capital Life Sciences Investors, LLC | 3.18% | 3.8M | $75.5M | −3.5M (−47.9%) | June 30, 2026 |
| 9 | Maverick Capital Ltd | 2.73% | 3.3M | $64.8M | +1.1M (+49.5%) | June 30, 2026 |
| 10 | Duquesne Family Office LLC | 2.57% | 3.1M | $60.9M | — | June 30, 2026 |
| 11 | Jupiter Topco LLC | 2.12% | 2.5M | $50.3M | +2.5M (0.0%) | June 30, 2026 |
| 12 | HHG PLC | 1.89% | 2.3M | $44.8M | −82,739 (−3.5%) | March 31, 2026 |
| 13 | Medicxi Ventures Management (Jersey) Ltd | 1.85% | 2.2M | $43.8M | −465,543 (−17.4%) | June 30, 2026 |
| 14 | Jennison Associates LLC | 1.76% | 2.1M | $41.7M | −648,117 (−23.6%) | June 30, 2026 |
| 15 | Orbis Allan Gray Ltd | 1.46% | 1.7M | $34.7M | +1.7M (0.0%) | June 30, 2026 |
| 16 | Polar Capital Holdings PLC | 1.44% | 1.7M | $34.2M | −1.1M (−39.1%) | June 30, 2026 |
| 17 | Capital Research & Mgmt Co - Division 3 | 1.44% | 1.7M | $34.2M | +282,364 (+19.6%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 1.29% | 1.5M | $30.6M | −401,463 (−20.6%) | June 30, 2026 |
| 19 | Westfield Capital Management Company, L.P. | 1.29% | 1.5M | $30.5M | −666,441 (−30.3%) | June 30, 2026 |
| 20 | Castle Hook Partners LP | 1.15% | 1.4M | $27.2M | +328,368 (+31.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 9.8M shares and 8 cut 7.6M.
NAMS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | American Funds SMALLCAP World A | 7.75% | 9.3M | $183.7M | +870,000 (+10.4%) | June 30, 2026 |
| 2 | Capital Group Global Equity Canada F | 2.11% | 2.5M | $50.0M | — | June 30, 2026 |
| 3 | Fidelity Contrafund | 1.95% | 2.3M | $46.1M | −762 (−0.0%) | August 31, 2026 |
| 4 | Strategic Advisers Fidelity US TtlStk | 1.92% | 2.3M | $45.4M | +53,505 (+2.4%) | August 31, 2026 |
| 5 | Fidelity Select Health Care | 0.82% | 980K | $19.4M | +132,400 (+15.6%) | August 31, 2026 |
| 6 | American Funds New Economy A | 0.80% | 957K | $19.0M | — | June 30, 2026 |
| 7 | Polar Capital Biotech S Inc | 0.69% | 823K | $16.3M | — | August 31, 2026 |
| 8 | Capital Group U.S. Small and Mid Cap ETF | 0.63% | 748K | $14.8M | +5,265 (+0.7%) | September 30, 2026 |
| 9 | Candriam Eqs L Biotech C USD Cap | 0.58% | 690K | $13.7M | +56,044 (+8.8%) | March 31, 2026 |
| 10 | Janus Henderson Hrzn Biotec E2 USD | 0.53% | 632K | $12.5M | +152,318 (+31.7%) | June 30, 2026 |
| 11 | iShares Biotechnology ETF | 0.50% | 603K | $12.0M | −4,568 (−0.8%) | September 30, 2026 |
| 12 | abrdn Healthcare Investors | 0.50% | 602K | $11.9M | +72,502 (+13.7%) | August 31, 2026 |
| 13 | JPMorgan Small Cap Growth A | 0.45% | 539K | $10.7M | −15,895 (−2.9%) | August 31, 2026 |
| 14 | PGIM Jennison Health Sciences Z | 0.45% | 534K | $10.6M | — | August 31, 2026 |
| 15 | American Century Small Cap Growth Inv | 0.44% | 524K | $10.4M | +91,985 (+21.3%) | June 30, 2026 |
| 16 | Fidelity Select Biotechnology | 0.44% | 524K | $10.4M | — | August 31, 2026 |
| 17 | Fidelity Small Cap Growth | 0.42% | 504K | $10.0M | — | July 31, 2026 |
| 18 | Fidelity Contrafund K6 | 0.42% | 496K | $9.8M | −1,258 (−0.3%) | August 31, 2026 |
| 19 | Fidelity Advisor Health Care I | 0.40% | 480K | $9.5M | +60,000 (+14.3%) | August 31, 2026 |
| 20 | Fidelity Stock Selector Small Cap | 0.39% | 472K | $9.4M | — | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NAMS insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-11 | Louis G Lange | Sell | $30.42 | 44,619 | $1.4M |
| 2026-03-09 | Johannes Jacob Piete Kastelein | Sell | $30.29 | 101,409 | $3.1M |
| 2026-03-06 | Johannes Jacob Piete Kastelein | Sell | $30.32 | 94,124 | $2.9M |
| 2026-03-06 | Louis G Lange | Sell | $29.41 | 28,186 | $828,950 |
| 2026-03-05 | Johannes Jacob Piete Kastelein | Sell | $30.30 | 104,467 | $3.2M |
| 2026-03-02 | Michael H Davidson | Sell | $33.25 | 443,707 | $14.8M |
| 2026-02-26 | Michael H Davidson | Sell | $33.71 | 183,332 | $6.2M |
| 2026-02-25 | Michael H Davidson | Sell | $35.30 | 58,253 | $2.1M |
| 2026-02-24 | Michael H Davidson | Sell | $36.15 | 64,708 | $2.3M |
| 2026-02-20 | Johannes Jacob Piete Kastelein | Sell | $35.31 | 45,481 | $1.6M |
| 2026-01-28 | Louise Frederika Kooij | Sell | $31.80 | 32,612 | $1.0M |
| 2026-01-27 | Louise Frederika Kooij | Sell | $32.62 | 39,816 | $1.3M |
| 2026-01-26 | Louise Frederika Kooij | Sell | $32.78 | 34,400 | $1.1M |
| 2026-01-23 | Louise Frederika Kooij | Sell | $33.75 | 38,172 | $1.3M |
| 2026-01-05 | Johannes Jacob Piete Kastelein | Sell | $33.25 | 6,000 | $199,500 |
| 2026-01-05 | Louise Frederika Kooij | Sell | $33.25 | 2,647 | $88,013 |
| 2025-12-26 | Louise Frederika Kooij | Sell | $35.30 | 43,872 | $1.5M |
| 2025-12-24 | Louise Frederika Kooij | Sell | $35.68 | 26,011 | $928,072 |
| 2025-12-23 | Louise Frederika Kooij | Sell | $36.21 | 75,117 | $2.7M |
| 2025-09-15 | James N Topper | Buy | $23.70 | 660 | $15,642 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
NAMS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NAMS
Institutional investors own 106.5% of NewAmsterdam Pharma's shares and insiders 0.90%. The largest holder is Frazier Life Sciences Management, L.P. with 15.13% of the shares (18.1M), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 8 reduced their stake in the latest filings. Short interest is 18.64% of the float, or 10.36 days of average trading volume. The share count rose 544.5% since 2020.
Related: NAMS analyst forecast, NAMS key metrics. See the NAMS stock overview for the latest quote and news.
NAMS ownership FAQ
Who owns the most NewAmsterdam Pharma stock?
The largest shareholders of NewAmsterdam Pharma are Frazier Life Sciences Management, L.P. (15.13%), Capital World Investors (10.23%), FMR Inc (8.65%), RA Capital Management, LLC (7.99%), FCPM III SERVICES BV (7.10%).
What percentage of NewAmsterdam Pharma is owned by institutions?
Institutions hold 106.5% of NewAmsterdam Pharma's shares outstanding; insiders hold 0.90%.
Which funds own NewAmsterdam Pharma?
The largest fund holders of NewAmsterdam Pharma are American Funds SMALLCAP World A (7.75%), Capital Group Global Equity Canada F (2.11%), Fidelity Contrafund (1.95%), Strategic Advisers Fidelity US TtlStk (1.92%), Fidelity Select Health Care (0.82%).
What is NewAmsterdam Pharma's short interest?
19.0M shares of NewAmsterdam Pharma were sold short, 18.64% of the float; at the average daily volume it would take 10.36 days to cover.
Are insiders buying or selling NewAmsterdam Pharma?
Of the latest 20 reported insider transactions in NewAmsterdam Pharma (since September 15, 2025), 1 were purchases and 19 were sales.
How many shares of NewAmsterdam Pharma are outstanding?
NewAmsterdam Pharma has 119.5M shares outstanding, of which 81.5M are in the public float.